In summary, both the non-selective BCL-2/BCL-XL inhibitor ABT737 and the selective BCL-XL inhibitor A1155463 exerted synergism to kill JMML cells in combination with azacitidine, and additionally targeted leukemia-initiating cells better than azacitidine. Here, BCL2 is linked to juvenile myelomonocytic leukemia.